China Sky One Medical (中国天字一号医药公司) is having a strong year-end finish in its new-product onslaught.  Today, the company announced SFDA production approval for two additional drugs, after receiving production approval for two other new products last week.  The most recent approvals are for Sodium Cromoglicate Eye Drops, a treatment of allergic conjunctivitis, and Ftibamzone Liniment a treatment of herpes and fungal skin infection.  The new products will be launched early in 2009. More details...

Stock Symbol: (NSDQ: CSKI)